S6/10Social
Dr Reddy’s shares crack 9% after weak Q1; these 3 brokerages slash their target prices
Dr Reddy’s shares plunged 9% on Thursday after the drugmaker reported a weak Q1 FY27 performance, with net profit tumbling 69% year-on-year to Rs 443 crore and revenue declining 6% to Rs 8,071 crore. Earnings were hit by a Rs 240 crore semaglutide API-related impact, including inventory provisions, while higher solvent and freight costs due to the Middle East conflict further squeezed EBITDA margins.
Click a tag to subscribe via email/Telegram (manage channels in Account).
⚠️ A model estimate of cascade risk — not a guarantee and not buy/sell. Calibration uses resolved outcomes only; monitor confirmation indicators below.
A
Эскалация
Forecast derived from cascade analysis. Watch confirmation indicators below.
Horizon: 7–30 days
Exact probability, cascade chain, and confirmation indicators unlock for approved members.
Checking access status…